About BG Medicine (OTCMKTS:BGMD)
BG Medicine, Inc. (BG Medicine) is a commercial-stage diagnostics company. The Company is engaged in commercializing diagnostic products that may be used to help guide the care and management of patients suffering from heart failure and related disorders. The Company's BGM Galectin-3 Test is an in vitro diagnostic device that employs a manual micro-titer platform to measure galectin-3 levels in blood plasma or serum for use as an aid in assessing the prognosis of chronic heart failure in conjunction with clinical evaluation. The automated galectin-3 tests are being developed and commercialized by its diagnostic instrument manufacturing partners and will be performed on its partners' automated platforms. The Company's CardioSCORE test is a multi-analyte biomarker-based blood test that was designed as an aid in the assessment of near-term risk for atherothrombotic cardiovascular events, such as heart attack and ischemic stroke.
Industry, Sector and Symbol
Industry MEDICAL CARE
Sub-IndustryLife Sciences Tools & Services
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Annual Sales$1.57 million
Price / Sales0.44
Price / CashN/A
Price / BookN/A
Return on EquityN/A
Return on AssetsN/A
BG Medicine (OTCMKTS:BGMD) Frequently Asked Questions
What is BG Medicine's stock symbol?
BG Medicine trades on the OTCMKTS under the ticker symbol "BGMD."
How were BG Medicine's earnings last quarter?
BG Medicine, Inc. (OTCMKTS:BGMD) issued its quarterly earnings results on Tuesday, November, 17th. The medical research company reported ($0.27) EPS for the quarter. The medical research company had revenue of $334 million for the quarter, compared to the consensus estimate of $695 million. View BG Medicine's Earnings History.
Who are some of BG Medicine's key competitors?
Some companies that are related to BG Medicine include Atlas Energy Group (ATLS), Cardinal Energy Group (CEGX), Digiliti Money Group (DGLT), KiOR (KIORQ), OmniTek Engineering (OMTK), Towerstream (TWER), Horsehead (ZINCQ), Lombard Medical Technologies (EVARF), Excel Maritime Carriers (EXMCQ), Alpha Natural Resources (ANRZQ), Iveda Solutions (IVDA), Blue Ridge Mountain Resources (MHRCQ), Inventergy Global (INVT), Bon-Ton Stores (BONT), GSE (GSEH), Atlas Resource Partners (ARPJQ), Quiksilver (ZQKSQ) and Goodrich Petroleum (GDPMQ).
Who are BG Medicine's key executives?
BG Medicine's management team includes the folowing people:
- Harry W. Wilcox III, Chairman of the Board
- Paul R. Sohmer M.D., President, Chief Executive Officer, Director
- Stephen P. Hall, Chief Financial Officer, Executive Vice President, Treasurer
- Aram Adourian Ph.D., Senior Vice President, Chief Scientific Officer
- Jeffrey R. Luber J.D., Independent Director
- James F. O'Connor CPA, Independent Director
- Stelios B. Papadopoulos Ph.D., Independent Director
Has BG Medicine been receiving favorable news coverage?
Media headlines about BGMD stock have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern rates the sentiment of press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. BG Medicine earned a daily sentiment score of 0.10 on Accern's scale. They also gave news stories about the medical research company an impact score of 45.93 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days.
How do I buy shares of BG Medicine?
Shares of BGMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is BG Medicine's stock price today?
One share of BGMD stock can currently be purchased for approximately $0.06.
How big of a company is BG Medicine?
BG Medicine has a market capitalization of $740,000.00 and generates $1.57 million in revenue each year.
How can I contact BG Medicine?
BG Medicine's mailing address is 303 Wyman Street Suite 300, Waltham MA, 02451. The medical research company can be reached via phone at 781-890-1199 or via email at [email protected]
MarketBeat Community Rating for BG Medicine (BGMD)MarketBeat's community ratings are surveys of what our community members think about BG Medicine and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
BG Medicine (OTCMKTS:BGMD) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
BG Medicine (OTCMKTS:BGMD) Earnings History and Estimates Chart
BG Medicine (OTCMKTS BGMD) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|4/4/2016||Q4 2015||($0.08)||$0.29 million||View||N/A|
|11/17/2015||Q315||($0.27)||$695.00 million||$334.00 million||View||N/A|
|5/14/2015||Q115||($0.03)||($0.04)||$1.60 million||$0.44 million||View||Listen|
|11/13/2014||Q3 2014||($0.28)||$0.70 million||View||N/A|
|8/14/2014||Q214||($0.06)||($0.06)||$1.40 million||$2.20 million||View||N/A|
|5/14/2014||Q114||($0.08)||($0.08)||$1.30 million||$0.74 million||View||N/A|
|3/20/2014||Q413||($0.12)||($0.06)||$1.10 million||$1.15 million||View||N/A|
|11/6/2013||Q3 2013||($0.68)||($0.52)||$1.02 million||$1.03 million||View||N/A|
|8/8/2013||Q2 2013||($0.20)||($0.18)||$1.27 million||$1.00 million||View||N/A|
|5/9/2013||Q1 2013||($0.27)||($0.21)||$1.16 million||$0.89 million||View||N/A|
BG Medicine (OTCMKTS:BGMD) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for BG Medicine (OTCMKTS:BGMD)
No dividend announcements for this company have been tracked by MarketBeat.com
BG Medicine (OTCMKTS BGMD) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 6.50%
BG Medicine (OTCMKTS BGMD) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|12/9/2015||Noubar Afeyan||Director||Sell||46,438||$0.56||$26,005.28|| |
|12/11/2014||Edwin M Kania Jr||Major Shareholder||Sell||634,390||$0.32||$203,004.80|| |
|1/30/2013||Stelios Papadopoulos||Director||Buy||250,000||$2.00||$500,000.00|| |
|11/19/2012||Brian S Posner||Director||Buy||10,000||$1.17||$11,700.00|| |
|11/15/2012||Stephane Bancel||Chairman||Buy||100,000||$1.26||$126,000.00|| |
BG Medicine (OTCMKTS BGMD) News Headlines
BG Medicine (OTCMKTS:BGMD) SEC Filings
This page is loading this company's SEC Filings. Please wait...
BG Medicine (OTCMKTS:BGMD) Income Statement, Balance Sheet and Cash Flow Statement
BG Medicine (OTCMKTS BGMD) Stock Chart for Wednesday, March, 21, 2018